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INTRODUCTION
Atopic dermatitis (AD) is one of the most common chronic in-
flammatory skin diseases, characterized by xerosis, eczematous 
skin lesions, pruritus, immunodysregulation, epidermal barrier 
dysfunction and IgE-mediated sensitization to food and envi-
ronmental allergens.1 Our understanding of the disease patho-
genesis of AD has increased, and it is clear that no single defect 
accounts for the array of clinical features associated with AD. 
Lifetime prevalence of AD varies from approximately 8% to 18% 
worldwide.2 AD is on the rise in many developing countries, af-
fecting over 10% of the population, and has reached a plateau of 
~20% in Western countries.3,4 The striking increase in AD inci-
dence observed in recent decades has been attributed to the re-
settlement of populations from rural to urban areas. According 
to the hygiene hypothesis,5 a lack of early childhood exposure to 
a variety of microbes results in reduced immune tolerance. 
Of the various pathogenic factors suggested for AD, impaired 
epidermal permeability barrier function is considered to be im-
portant. Many studies have suggested that a defective epider-
mal barrier combined with an abnormal immune response 
might contribute to the pathophysiology of AD, supporting the 
outside-inside hypothesis.6,7 In addition, the clinical manifesta-
tions of AD predate the development of asthma and allergic rhi-
nitis, suggesting that AD is an entry point for subsequent aller-
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gic disease in a process called the atopic march. The concept of 
atopic march was hypothesized to describe the progression of 
atopic disorders from AD in infants to asthma and allergic rhini-
tis in children. Kubo et al.1 suggested a theoretical model of bar-
rier disruption followed by percutaneous sensitization, which 
may apply to the pathogenesis of the atopic march. Therefore, 
the importance of barrier disruption in AD has gained increas-
ing attention. In this review, we discuss the recent progress in 
understanding the functions of the epidermal permeability bar-
rier, its immunologic role in human and animal subjects, and 
barrier repair therapies in AD.
Epidermal permeability barrier dysfunctions in AD 
The skin, as an interface between the organism and the exter-
nal environment, plays a major role in protecting and support-
ing the life it encloses. The outermost layer of the skin, the stra-
tum corneum (SC), is the primary mediator of this epidermal 
permeability barrier function.8 Atopic dry skin displays impaired 
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barrier function, indicated by an increased transepidermal wa-
ter loss (TEWL) and decreased water-binding capacity due main-
ly to altered levels of inter/intracellular components in the SC.
Filaggrin and its gene
Filaggrin (FLG) is named after the filament aggregating pro-
tein, and the FLG gene is located on chromosome 1q21 within 
the epidermal differentiation complex.9 FLG protein is local-
ized in the stratum granulosum (SG). Profilaggrin, a 400-kDa 
polyprotein, is the main component of keratohyaline granules. 
In the process of keratinocyte differentiation, profilaggrin is de-
phosphorylated and cleaved into 10-12 FLG molecules. In vitro, 
FLG monomers aggregate and align keratin bundles, which 
contribute to the mechanical strength and integrity of the SC.6 
To promote corneocyte compaction, FLG monomers are de-
graded into their constituent amino acids, including glutamine, 
arginine and histidine. These amino acids are then hydrolyzed 
further into acidic polycarboxylic acid osmolytes, which main-
tain SC hydration (the so-called natural moisturizing factors, 
NMFs), by caspase 14, peptidylarginine deiminases or bleomy-
cin hydrolase to maintain hydration of the upper SC and to re-
duce skin surface pH.5,10 Maintaining acidic pH is key for many 
protective functions, including permeability barrier homeosta-
sis, SC integrity and cohesion, antimicrobial defense, and it is 
important for the activation of enzymes involved in ceramide 
metabolism and modulation of the serine protease cascade re-
quired for coordinated epidermal differentiation and cornified 
cell envelope formation.6,11 Moreover, FLGs are crucial proteins 
for terminal differentiation of epidermal keratinocytes, which 
form a skin barrier with the SC intercellular lipids. Pyrrolidone 
carboxylic acid, a major component of NMFs in skin, is primar-
ily produced from FLG proteins in the SC and plays a vital role 
in maintaining hydration of the SC.8 If these proteins are de-
creased or absent due to FLG mutations, the FLG-associated SC 
barrier is disrupted. Such SC barrier disruption results in de-
creased formation and secretion of the lamellar body (LB), cor-
nified envelope, and corneodesmosome, elevated pH and de-
creased tight junction (TJ) proteins, leading to increased epi-
sodes of percutaneous allergen exposure (Fig. 1).1 Kezic et al.12 
confirmed that individuals with FLG-null mutations have signif-
icantly reduced levels of NMFs in the SC of their forearms and 
palms. Moreover, significantly lower NMF levels were observed 
in individuals with a history of AD who were carriers of FLG mu-
tations compared with those who were non-carriers. The au-
thors demonstrated higher TEWL in the carriers of FLG muta-
tions compared with non-carriers. FLG has been suggested to 
contribute to the formation of acid mantle (described below) 
within the SC through the production of urocanic acid (UCA) 
via the filaggrin-histidine-UCA cascade.13 Consequently, FLG-
deficiency in AD lesions leads to defects in the formation of the 
cornified envelope, a decreased ability to maintain SC hydra-
tion, and a parallel elevation in pH. The increase in pH enhanc-
es the KLK5 and KLK7 activities, which are optimal at neutral 
pH, resulting in over-degradation of corneodesmosomes and 
decreased SC integrity and cohesion. Patients with FLG muta-
tions might have a higher risk of allergic sensitization compared 
with those with wild-type FLG.14 FLG mutations are significant-
ly correlated with increased risk of developing atopic diseases, 
including AD, atopic asthma, allergic rhinitis and nickel and 
food allergies, even though FLG is not found in the bronchial 
epithelium.15 
Nevertheless, FLG null mutations may not be sufficient to in-
duce the findings typical of AD. The median prevalence of FLG 
mutations among Europeans and Asians is 7.7% and 3.0%, re-
spectively.16 In European studies, the prevalence of FLG muta-
tions in AD subjects is 3% in Italy, 15.2%-22.9% in Germany, 
40.2%-42% in the UK and 45.2%-55.8% in Ireland, and this pat-
tern suggests a higher tendency for FLG mutation prevalence in 
AD patients who reside in countries of higher latitudes than in 
those of lower latitudes.16 Patients with FLG mutations can de-
velop ichthyosis vulgaris without manifestations of AD, and ap-
proximately 50%-90% of AD patients have no FLG defects.16,17 In 
fact, mice with the FLG null mutation exhibited no spontane-
ous AD-like skin lesions.18 However, flaky tail mice homozygous 
for the 5303delA mutation in the FLG and Tmem79/Matt genes 
showed FLG and NMF deficiencies, presumably representing 
the characteristics of AD after exposure to allergens.19 A recent 
study revealed that the matted gene Matt is a predisposing gene 
for AD in mice, and a common Matt (Pl use consistent designa-
tions when describing flaky tail mice in this section and later in 
the manuscript) single nucleotide polymorphism is associated 
with AD in human subjects.19 In addition, Sasaki et al.20 showed 
that the Tmem79 (ma/ma) mutation is responsible for the spon-
taneous dermatitis phenotype in matted mice, probably due to 
the impairment of the lamellar granule secretory system and al-
tered SC barrier function, which has also been identified in 
Caucasians with FLG mutations in a dose-dependent manner.21 
Fig. 1. Barrier dysfunction associated with filaggrin deficiency leads to lipid bi-
layer disorganization, delayed bilayer maturation, as well as decreased SC cohe-
sion, paracellular permeability barrier, and photoprotection, which all may play 
important roles in the pathogenesis of atopic dermatitis (AD). NMF, natural mois-
turizing factors; SC, stratum corneum; TEWL, transepidermal water loss.
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A recent study by Kim et al. showed that IL-25 inhibits the ex-
pression of FLG and acts synergistically with Th2 cytokines to 
inhibit FLG expression.22 We assume that the barrier breakage 
in AD is due not only to the FLG gene alone, but that FLG com-
bined with other genes might cause or exacerbate AD skin le-
sions.
TJ barrier
TJs are involved in the control of paracellular migration of in-
flammatory cells. Increasing evidence shows that skin TJs, which 
localize in the SG, contribute to epidermal barrier formation,23 
however, the role of TJs in AD is still unknown. Among TJ pro-
teins, claudin (Cldn)-1, a TJ-specific integral membrane pro-
tein, and Cldn-4 play important roles in the barrier function of 
the skin. In a recent study, Cldn-1 knockout mice demonstrat-
ed normal SC structure but abnormal SC formation and SC 
barrier defects. These Cldn-1 knockout mice died shortly after 
birth and had increased TEWL.24 In humans, a lack of Cldn-1 
causes NISCH syndrome, which is characterized by ichthyosis, 
scalp hypotrichosis, scarring alopecia, neonatal sclerosing 
cholangitis and leukocyte vacuolization. Kubo et al.25 reported 
that dendrites of activated Langerhans cells express Cldn-1 and 
ZO-1. Therefore, functional bicellular and tricellular TJs, which 
can take up external allergens easily when the SC barrier is dis-
rupted, are present between Langerhans cells and keratino-
cytes.1 In a recent study, patients with AD demonstrated a de-
fect in TJ barrier function and composition.26 Furthermore, 
Yuki et al.27 reported that impaired TJ barriers affect polar lipids 
and profilaggrin processing by disturbing the pH of the SC. 
Based on these reports, we assume that decreased TJ compo-
nents in lesional AD promote epicutaneous penetration of al-
lergens, including the house dust mite antigen, which leads to 
the increased possibility of developing systemic allergy or atop-
ic march. Recently, Kuo et al.28 showed that the activation of 
toll-like receptor (TLR)-2, which shows reduced expressed in 
AD, enhances TJ function in mice and human keratinocytes, 
suggesting the use of TLR-2 enhancers as a potential therapeu-
tic strategy in patients with AD. Further investigation of the 
crosstalk between TJs and the SC barrier is needed to clarify the 
role of TJs in the pathogenesis of AD.
PH, proteases and protease activated receptor (PAR) 2 
The skin surface pH, which ranges from 4.5 to 5.5 in humans, 
is slightly acidic compared with the normal physiologic pH.8 
The importance of pH in vivo was first reported in experiments 
in which the permeability barrier function was disrupted acute-
ly, producing a parallel increase in pH.29 The pH of the SC influ-
ences key epidermal functions, including permeability barrier 
homeostasis, desquamation of corneocytes, initiation of inflam-
mation, processing of secreted LB polar lipids and antimicrobi-
al defense (Fig. 2A). The UCA breakdown products, free fatty ac-
ids and sodium hydrogen antiporter (NHE1) are the three main 
factors responsible for maintaining acidic pH in the skin.9 In AD, 
the baseline skin pH is more alkaline than the average baseline 
pH of healthy skin.30 The perturbation of lipid metabolism and 
its molecular organization as well as elevated skin pH induce 
the growth of bacteria such as Staphylococcus aureus (S. aureus).
Trans-UCA (t-UCA) is an endogenous acidifier of the SC. Hence, 
decreased production of FLG products could result in an initial 
increase in skin surface pH that is sufficient to activate multiple 
serine proteases in SC, which exhibit neutral-to-alkaline pH 
optima.31 If prolonged, the pH-induced increase in serine pro-
tease activity could precipitate downstream structural and 
functional alterations, as mentioned below (Fig. 2B). Moreover, 
increased pH leads to higher activities of Kallikrein (KLK) 5 and 
7 (SC chymotryptic enzyme), which have optimal activity at 
neutral pH, resulting in the over-degradation of corneodesmo-
somes and a decrease in SC integrity and cohesion.13 Moreover, 
elevated skin pH inhibits the activity of lipid-processing en-
zymes, including β-glucocerebrosidase (β-GlcCer’ase), acid 
sphingomyelinase (aSMase) and secretory phospholipase A2 
(sPLA2), which are essential in the production of ceramide and 
free fatty acids, thereby causing impaired lipid processing and 
defects in the epidermal permeability barrier.
SC acidity is important in antimicrobial barrier function in 
that it inhibits the growth of pathogens. The growth of S. aureus, 
which readily colonizes in the lesional skin of AD, is normally 
inhibited at low skin pH and grows best at pH 7.5. In AD, the in-
creased pH in lesional skin leads to bacterial growth, resulting 
in allergic inflammation and aggravation of AD. Hatano et al.11 
showed that the acidification of SC alone substantially prevents 
the development of barrier abnormalities and downstream im-
mune abnormalities during the elicitation phase in the murine 
oxazolone-induced AD model. This study suggests that the 
maintenance of a normal or hyperacidic pH could be a possible 
novel treatment for reversing or preventing AD in humans.
PAR is a G protein-coupled receptor, characterized by a unique 
mechanism of self-activation following specific proteolytic 
cleavage of its extracellular domain.13 Four PAR members have 
been identified: PAR-1, -3, and -4 are activated by thrombin and 
are involved in homeostasis and thrombosis, whereas PAR-2 is 
activated by trypsin-like serine proteases, but not by thrombin. 
PAR-2 is widely distributed throughout the mammalian body13 
and is expressed by almost all skin cell types, especially kerati-
nocytes. Previous studies demonstrated that PAR-2 is expressed 
in the suprabasal epidermal layers of both humans and mice, 
and that this expression is most prominent in the granular lay-
er, implying that PAR-2 expression might depend on the state of 
epidermal differentiation.32 PAR-2 localizes in the suprabasal 
layers of the mouse and human epidermis with high levels in 
the SG, supporting PAR-2 as the primary sensor of barrier-initi-
ated serine protease activity.33 The lesional skin of AD expresses 
high levels of PAR-2. Furthermore, PAR-2 activation is likely to 
be involved in pruritus of AD.13 Indeed, high expression rates of 
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PAR-2 and trypsin have been observed in the lesional skin of 
patients with AD, and PAR-2 agonist peptides induce pruritus 
in patients with AD.34 PAR-2 in the skin is involved in pruritus 
via the transient receptor potential vanilloid receptor (TRPV1) 
inflammation, and thymic stromal lymphopoietin (TSLP) acti-
vation, implying that PAR-2 antagonists represent potentially 
useful therapeutics for treating AD (Fig. 3).35 The association 
between PAR-2 and TSLP is discussed below.
Many studies have provided evidence that genes associated 
with proteases/protease inhibitors become deregulated in pa-
tients with AD, shifting the balance between proteases and pro-
tease inhibitors toward increased protease activity. A link has 
been demonstrated between AD and a 4-base pair (AACC) in-
sertion into the 3’-untranslated region of the KLK7 gene, which 
increases the half-life of KLK7 mRNA and the enzymatic activi-
ty of KLK7.13 Lymphoepithelial Kazal-type-related inhibitor 
(LEKTI) is an inhibitor of multiple serine proteases in skin, and 
it regulates the enzymatic activities of serine proteases, includ-
ing KLK5, -6, -7, -13, and -14, thereby controlling epidermal 
barrier function.36 A premature stop codon mutation in the 
SPINK5 gene, which encodes LEKTI, is associated with Nether-
ton syndrome (NS), a rare ichthyosiform dermatosis character-
ized by congenital ichthyosiform erythroderma, severe atopic 
manifestations and hair shaft abnormalities. SPINK5-deficient 
mice demonstrate increased proteolytic activities of KLK5 and 
KLK7 in the epidermis and abnormal degradation of desmo-
glein 1, resulting in abnormal corneodesmosome cleavage and 
premature desquamation. These data suggest that LEKTI is a key 
regulator of KLK5 and KLK7 activity, and defective SC adhesion 
caused by epidermal protease hyperactivity is the primary 
pathogenic event in NS.13 In addition, several studies reported 
that the polymorphisms in the SPINK5 gene are associated with 
AD.37,38 Moreover, cystatin A, a cysteine protease inhibitor, inhib-
its the endogenous cathepsins B, -H, and -L and the exogenous 
proteases from house dust mites of dermatophagoides pteron-
yssinus (Der p) 1 and dermatophagoides farinae (Der f) 1.13,39 
The cystatin A-encoding gene (CSTA) polymorphism (+344c 
variant) is associated with AD.39 This CSTA variant causes re-
duced levels of cystatin A in the skin surface and in sweat, allow-
ing exogenous proteases to break down the integrity of the SC, 
which enhances the penetration of allergens and aggravates AD. 
These genetic variants in protease and protease inhibitor genes 
Fig. 2.  The factors involved in 
acidic pH maintenance and their 
role in normal epidermis, and the 
consequences of altered pH in 
patients with AD. (A) Exogenous 
free fatty acids are derived from 
sweat glands or catalyzed from 
sebaceous gland-derived triglyc-
erol moieties via microorganism-
secreted lipases. Endogenous 
free fatty acids are derived from 
phospholipids by phospholipase 
A2 (PLA2), both of which are se-
creted by lamellar bodies (LBs) at 
the SC–stratum granulosum junc-
tion. Additionally, the Na+/H+ an-
tiporter is involved in maintaining 
the skin acid mantle. Therefore, 
the skin acid mantle regulates SC 
integrity and cohesion, antimicro-
bial function, processing of LB 
polar lipids, structural organiza-
tion of lamellar membrane, and 
β-glucocerebrosidase/sphingo-
myelinase function. (B) AD or oth-
er stressors alter the function of 
the skin acid mantle. The altered 
acid mantle increases serine pro-
tease activity and decreases the 
function of corneodesmosomes, 
resulting in decreased production 
of ceramides and LB secretion, 
altered SC cohesion and inflam-
mation activation.
A
B
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coexist in some patients with AD, resulting in a more severe de-
fect in the skin barrier.13
The proteolytic activity from various contact allergens and 
aeroallergens are considered important factors in the initiation 
and aggravation of AD. Proteolytic activity plays a role in the 
pathogenesis of allergic diseases, including allergic rhinitis, 
asthma and AD, by inducing Th2 allergic inflammation and di-
rectly affecting the structure and function of the epidermal bar-
rier, which facilitates further penetration of allergens through 
the defective skin barrier.40 House dust mite and cockroach al-
lergens, important environmental factors in the pathogenesis 
of AD, have been shown to have proteolytic activity.41 House 
dust mite allergens contain several cysteine and serine proteas-
es. The serine proteases from the mite allergens, Der p 3 and 
Der p 9, activate PAR-2 on keratinocytes to produce cytokines 
and contribute to the pathogenesis of AD, whereas the cysteine 
protease activity in Der p 1 stimulates inflammation via a PAR-
2-independent mechanism. S. aureus produce extracellular V8 
protease, which causes defective epidermal permeability barri-
er function in the skin of hairless mice by directly degrading 
DSG1.42 These reports imply that proteolytically active allergens 
could break down the skin barrier via PAR-2-mediated inhibi-
tion of LB secretion or PAR-2-non-mediated mechanisms, in-
cluding the degradation of corneodesmosomal proteins and 
lipid processing enzymes. This degradation further triggers al-
lergen penetration through the disrupted epithelial barrier to 
aggravate Th2-mediated inflammation and possibly causes the 
non-IgE-associated form of AD (atopiform AD) to switch to the 
typical IgE-associated form of AD.13 Various roles of serine pro-
teases and PAR-2 are described in Fig. 3.
Peroxisome proliferator-activated receptors (PPARs)
PPARs are ligand-activated transcription factors involved in 
the genetic regulation of lipid metabolism and energy homeo-
stasis. PPARs belong to a subfamily of nuclear hormone recep-
tors comprising three different isoforms of PPARs: PPARα, 
PPARβ/δ and PPARγ.43 After ligand binding, PPARs can regulate 
gene expression by binding to peroxisome proliferator response 
elements in target genes, after heterodimerizing with the reti-
noid X receptors. Activators of PPARs and liver X receptors dis-
play potent but largely positive effects on the epidermal struc-
ture and function in normal and diseased skin, including the 
upregulation of FLG, anti-inflammatory activity, and reverse 
epidermal hyperplasia and differentiation.44 In AD, PPARs re-
duce several inflammatory mediators in the skin and regulate 
epidermal barrier homeostasis by stimulating epidermal differ-
entiation and lipid production. In fact, PPAR ligands inhibit T 
helper cell responses by inhibiting IL-2 production in T cell 
clones.45 Since patients with AD exhibit primary abnormalities 
in the epidermal barrier function, the PPAR/LXR activators 
might possess potential utility in AD by stimulating epidermal 
differentiation and lipid production.44 Lower expression of 
PPARα is observed in AD lesional skin, suggesting that decreased 
PPARα signaling might be involved in the relationship between 
permeability barrier abrogation and allergic inflammation in 
AD.46 Experiments using PPARα knockout mice revealed a 
modest decrease in the epidermal expression of differentiation 
markers (profilaggrin and loricrin), a thinner SG than that in 
wild type mice, decreased keratohyaline granules, normal per-
meability barrier function and decreased β-GlcCer’ase activi-
ty.47 Indeed, the combined therapy of topical PPARα activators/
ligands and steroids showed not only potent anti-inflammatory 
benefits in the murine AD model, but also almost no rebound 
flares, which is one of the considerable side effects of steroid 
therapy.48 Furthermore, PPARα prevents the side effects of ste-
roid-induced structural and functional abnormalities and im-
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TLR-2
IL-6, IL-12 ↑
Inflammation ↑
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Fig. 3. The roles of serine protease and PAR-
2 in AD. AMP, antimicrobial peptide; FLG, fil-
aggrin; KLK, kallikrein; LB, lamellar body; LE-
KTI, lymphoepithelial Kazal-type-related in-
hibitor; LTN, lipoglycan; PAR-2, protease ac-
tivated receptor-2; PGN, peptidoglycan; TLR, 
toll-like receptor; TSLP, thymic stromal lym-
phopoietin.
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proves paracellular permeability.48 Recent analysis of AD skin 
lesions showed increased PPARγ expression in keratinocytes 
and in infiltrating T cells and monocytes.49 PPARγ plays a criti-
cal role in the regulation of genes involved in cellular prolifera-
tion, in specific components of the Th2 inflammatory pathway 
and in maintenance of the skin barrier.45 Systemic treatment with 
a PPARγ agonist, rather than with topical treatment, decreased 
the amount of surface area affected, the severity of lesions and 
the number of flares in patients with severe AD.50 Therefore, 
PPARs and their corresponding ligands are potential therapeutic 
targets for treating AD. Further studies are needed to verify the 
underlying mechanism of PPARs in AD pathogenesis.
Ceramides and lipid processing
The major lipid species of the SC are ceramides, fatty acids 
and cholesterol. The majority of SC lipids are derived from the 
LB and synthesized in the keratinocytes of the upper stratum 
spinosum and SG.8 In human AD, a selective reduction in ce-
ramide content, especially ceramide 1, is observed. Indeed, Na-
kajima et al.51 reported that a ceramide deficiency in the epider-
mis leads to psoriasis-like lesions in the serine palmitoyltrans-
ferase knockout mouse model. The abnormal neutral skin pH 
in patients with AD inhibits the activity of lipid-processing en-
zymes, including β-GlcCer’ase, aSMase and sPLA2, thereby 
causing impaired lipid processing and a defective lipid barrier, 
as mentioned above. Other minor mechanisms that might ac-
count for the frequently colonized microbial pathogens in AD 
involve acidic ceramidase activity, which could decrease ce-
ramide content.52 Moreover, altered ceramide metabolism in 
AD results in decreased levels of sphingosine, which is pro-
duced from ceramide by ceramidase in the SC. Since sphingo-
sine is known to have a powerful antimicrobial activity on S. au-
reus at physiologic levels, downregulation of sphingosine is one 
explanation for the susceptibility of patients with AD to S. aure-
us colonization.37,38 
Antimicrobial peptides
Antimicrobial peptides (AMPs) are important molecules in-
volved in the evolutionarily conserved innate immune defense 
system of the skin against bacteria, viruses, fungi, parasites and 
tumor cells.53 More than 1,700 AMPs have been identified.54 In 
normal human skin, keratinocytes are the main source of AMPs, 
and AMP synthesis occurs primarily in the SG.53 In addition to 
their antimicrobial activity, AMPs in the skin have variable 
functions, including modulation of host inflammatory respons-
es and promotion of wound healing.55 Moreover, AMPs have 
been shown to be associated with permeability barrier function 
in a knockout mouse model for cathelin-related antimicrobial 
peptide (CRAMP), a murine homologue of LL-37. These knock-
out mice showed a significant delay in permeability barrier re-
covery after tape stripping as well as structural abnormalities in 
LB content.56 In addition, a recent study suggested that human 
β-defensin-2 (HBD2) can be used as a marker for disease sever-
ity and barrier properties in AD.53 
AD skin has significantly lower AMP production than does pso-
riatic skin, while both disorders are associated with inflamma-
tion and defective barrier function.57 Nomura et al.58 proposed 
that this defect in AD is caused by AMP suppression via elevated 
levels of T-helper 2 cytokines, IL-4 and IL-13. Lower AMP levels 
diminished the antimicrobial barrier function in AD subjects, re-
sulting in increased susceptibility to S. aureus and other microbi-
al superinfections, such as eczema herpeticum.53,59 In fact, LL-37 
exhibited antiviral activity against herpes simplex virus (HSV), 
and mice deficient in the LL-37 homologue showed higher levels 
of HSV-2 replication in their skin. Moreover, the skin of AD sub-
jects with eczema herpeticum exhibited significantly lower levels 
of LL-37 than that of AD patients. Therefore, reduced levels of LL-
37 may render AD subjects susceptible to eczema herpeticum.59,60 
Many reports have demonstrated that AMPs are induced in 
the skin in AD. Reduced gene expression of hBD-3 was not ob-
served in the epidermis of patients with AD compared with 
psoriasis,60 and increased expression levels of hBD-3 and other 
AMPs, such as hBD-2, psoriasin, elafin and calprotectin, were 
found in AD skin compared with healthy skin.61 However, an-
other study did not detect differences in hBD-2 and LL-37 ex-
pression levels between the nonlesional skin of AD patients 
and non-AD patients, indicating that expression of hBD-2 and 
LL-37 is not decreased at baseline in the epidermis of patients 
with AD.62 Ballardini et al.63 and Gambichler et al.64 detected 
higher levels of AMPs in lesional skin than in nonlesional skin 
in AD. Based on these contradictory reports, we assume that 
the increased AMP amounts are lower at the onset of inflam-
mation in the lesional skin in AD patients compared with that 
in non-AD patients. Further studies are needed to clarify the 
causality of AMP expression on lesional and non-lesional epi-
dermis in AD.
Ultraviolet irradiation and AD
Ultraviolet (UV) C radiation is absorbed by the ozone layer; 
however, the skin is constantly exposed to UVA and UVB irradi-
ation, and this UV radiation affects FLG degradation. Using his-
tidine as a substrate, histidase produces t-UCA, a major UVB-
absorbing epidermal chromophore. t-UCA is photoisomerized 
to cis-UCA with UVB exposure, and cis-UCA may produce oxi-
dative DNA damage and initiate the translation of genes associ-
ated with apoptosis and immunosuppression.16,65 Although UV 
irradiation of the skin induces disruption of the epidermal bar-
rier, phototherapy is generally used in patients with AD to re-
lieve acute flares (UVA1) and chronic lesions (narrow band 
UVB).66 The mechanism of action in AD has not been elucidat-
ed; however, the proper UV dose has positive effects on the epi-
dermal permeability barrier function by immunomodulating 
apoptosis of inflammatory cells, reducing the number of cuta-
neous nerve fibers, inhibiting the Langerhans cells and altering 
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cytokine production.67 In addition, a suberythemal dose of UVB 
on the skin exerts beneficial effects on the SC barrier function 
by activating the cutaneous vitamin D system.68,69 In addition, 
UV initiates endoplasmic reticulum (ER) stress responses in-
cluding downstream activation of the transcription factor, NF-
κB.70 In the epidermis, ER stress increases human cathelicidin 
antimicrobial peptide (CAMP) expression, which stimulates in-
nate immunity.71 A recent study suggested that UV radiation 
enhances cortisol activity in a waveband-dependent manner, 
and cortisol production protects and/or restores epidermal 
barrier homeostasis.72 In fact, most patients affected by AD im-
prove during the sunny summer season, and artificial UV radi-
ation, including psoralen-UVA and narrow-band UVB, is fre-
quently utilized in the treatment of AD. Further comparative 
clinical studies are needed to clarify the proper dose and wave-
length of UV therapy in AD.
Link between the epidermal permeability barrier function and 
the systemic immune reaction in ad: thymic stromal 
lymphopoietin (TSLP)
TSLP is an interleukin-7-like cytokine produced by epithelial 
cells that triggers dendritic cells to induce Th2 inflammatory re-
sponses.73 TSLP enhances the effector stage of the allergic re-
sponse and amplifies secretion of Th2 cytokines in synergy with 
IL-1 and TNF-α.74 Furthermore, TSLP is induced by exogenous 
stimuli, such as defects in barrier differentiation, infections, TLR 
ligation and trauma, as well as by topical application of active 
vitamin D3 and low-calcemic analogue treatment.75 TSLP is 
overexpressed in keratinocytes in AD skin lesions and triggers a 
pathway underlying AD progression and atopic march. In addi-
tion to early protection from skin barrier defects in AD, the se-
lective inhibition of TSLP might be a key intervention strategy 
to block the progression of atopic march. Previous studies have 
reported increased levels of TSLP in tissues biopsied from acute 
and chronic AD skin lesions and from the serum of patients with 
AD.76 Overexpression of TSLP in epidermal keratinocytes is a 
systemic driver of bronchial hyperresponsiveness, and TSLP in 
asthmatic airway epithelial cells is correlated with reduced lung 
function.77 The PAR-2–TSLP relationship, in particular, has been 
emphasized in many studies.35 Indeed, PAR-2 might be a parent 
signal that induces the overexpression of TSLP in epithelial cells.78 
A recent study revealed high TSLP expression when keratino-
cytes of flaky tail mice were exposed to a PAR-2 agonist, but low 
TSLP expression in the presence of a PAR-2 antagonist, suggest-
ing that PAR-2 is at least partly responsible for the induction of 
TSLP production.79 These results suggest that TSLP could be a 
link between skin barrier function and the systemic immune 
reaction in AD. 
Animal models in AD
Many research groups have established animal models of AD. 
In this section, we discuss several AD animal models that have 
been used most frequently and which seem to correlate with 
the outside–inside hypothesis in AD. Flaky tail mice have been 
used to investigate the role of FLG in AD. The spontaneous flaky 
tail (ft) mouse arose on the background of an existing recessive 
hair phenotype, matted (ma). Flaky tail mice have a 1-bp frame-
shift mutation in the FLG gene. Flgft mice have spontaneous 
dermatitis with increased IgE levels, endogenous protease (KLK5, 
7, and 14) activity, TSLP expression, and basophil accumula-
tion in the skin, showing many characteristics of AD.79 They ap-
pear normal at birth, and the flaky phenotype becomes visible 
3 days after birth with the presence of dry scaly skin and tail 
constrictions. Under specific pathogen-free conditions, the ma-
jority of Flgft mice developed clinical and histological eczema-
tous skin lesions similar to human AD with outside-inside skin 
barrier dysfunction, as evaluated by newly devised methods.80 
Moreover, the topical application of dermatophagoides pteron-
yssinus in Flgft mice induces skin lesions that are clinically and 
histologically similar to those seen in AD.79 The relative contri-
bution of Flg and ma to the compound phenotype has yet to be 
defined fully. As mentioned above, the matted mouse gene is a 
predisposing gene for AD, and the Tmem79 (ma/ma) mutation 
is responsible for the spontaneous dermatitis phenotype in mat-
ted mice, which can also be found in Caucasians with FLG mu-
tations in a dose-dependent manner.21 Based on these reports, 
the flaky tail mouse is perhaps the most represented animal 
model of AD corresponding with FLG mutation in human AD.
Oxazolone (Ox) is commonly used to provoke allergic contact 
dermatitis, and it evokes a Th1-dominated response to the hap-
ten.81 However, multiple challenges of Ox to the skin of hairless 
mice over an extended period cause the skin inflammation to 
shift from a Th1-dominated delayed type hypersensitivity re-
sponse to a chronic Th2-dominated inflammatory response 
similar to human AD.11,44,48,81,82 Nine to 10 Ox challenges to hair-
less mice produced a chronic Th2-like skin inflammation, which 
was characterized by dermal infiltration of Th2 lymphocytes 
(expressing CRTH2), mast cells and eosinophils, increased ex-
pression of IL-4 in the dermis and highly elevated IgE levels. 
Repeated Ox challenges led to increased epidermal hyperplasia 
and decreased expression of keratinocyte differentiation mark-
ers. Skin barrier abnormalities were associated with increased 
TEWL. Additionally, impaired LB secretion along with decreased 
SC ceramide content and hydration resulted in reduced lamel-
lar membranes, similar to those observed in patients with AD. 
Furthermore, as in human AD, increased epidermal serine pro-
tease activity in the SC and decreased expression of 2 LB-de-
rived antimicrobial peptides (CRAMP and mBD3) paralleled 
the decrease of their human homologues in AD skin lesions. Al-
though the repeated hapten sensitization model is not geneti-
cally driven, this model may be applicable to the acquired form 
of AD with respect to extrinsic allergens. Because of its repro-
ducibility, predictability, low cost, and relative rapidity, the re-
peated Ox sensitization model could be useful for evaluating 
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pathomechanisms and potential treatments for AD.
Nc/Nga mice, an inbred mouse strain reported by Matsuda et 
al., provided the first model of murine AD.83 Nc/Nga mice have 
mutations on chromosome 9 linked to increased IgE production 
and Th2 responses. Skin lesions develop spontaneously in Nc/
Nga mice after exposure to various exogenous aeroallergens, 
closely mimicking human AD. In addition, Nc/Nga mice show 
skin barrier abnormalities with increased TEWL and abnormal 
skin conductivity under conventional conditions and impaired 
ceramide metabolism.84 However, Yagi et al.85 suggested that 
AD-like skin changes in Nc/Nga mice are IgE/Th2-independent 
because STAT6-deficient Nc/Nga mice exhibit skin changes, 
comparable to those of STAT6-positive Nc/Nga littermates, and 
undetectable IgE serum levels. Therefore, the Th2-mediated 
immune response is not necessary for the development of AD-
like skin disease in Nc/Nga mice.86
Several studies have employed the occlusive patch of ovalbu-
min (OVA) to generate AD and allergic march models. Although 
asthma-like lung lesions developed in these models, AD-like 
skin lesions, including eczematous lesions, and disrupted SC 
barrier function did not fully develop. Zhu et al.87 used IL-13 
transgenic mice treated with OVA. Demehri et al.88 used RBP-
jCKO mice treated with OVA, and Hershko et al.89 used Ox chal-
lenge with OVA treatment. Although all of these models ex-
pressed AD-like skin lesions combined with asthma-like lung 
lesions, the methods relied on intraperitoneal injections of OVA 
for sensitization, not epicutaneous sensitization via damaged 
skin barriers. We suggest that the allergic march model corre-
lating with the outside-inside hypothesis might be generated 
using topically applied allergens (such as house dust mites) 
onto AD-like skin lesions of Flgft mice, Ox-induced AD model 
mice and Nc/Nga mice with disrupted barriers. In addition, in-
halation of the allergens might reveal physiologic mechanisms 
of allergen penetration, systemic circulation, and allergen chal-
lenges.
Barrier repair therapy in AD
Although anti-inflammatory treatments might reduce the dis-
ease severity by suppressing the immune reaction, they do not 
fully correct the primary underlying barrier abnormalities that 
drive disease pathogenesis in AD. The ideal emollients for bar-
rier repair therapy should normalize the epidermal barrier 
function by reducing TEWL, improving SC hydration and pro-
tecting the skin from allergen penetration. AD treatment must 
aim to restore the barrier and its function, as well as suppress 
inflammation and control the pruritus. In addition, it is impor-
tant to educate patients by highlighting the chronic nature of 
AD, the importance of maintenance therapy and the need for 
prompt suppression of flare-ups.90 General considerations and 
approaches to treating AD by restoring the barrier system in-
clude education (about soaps, hydration and lowering stress 
levels), hydration (using emollients to decrease the use of ste-
roids), decreasing S. aureus carriage, breaking the itch-scratch 
cycle use of antihistamines, which are also helpful for barrier 
function,91 reduction of pH in the SC (hyperacidification),11 and 
use of epidermal barrier-enhancing agents, including serine 
protease inhibitors, topical PAR2 antagonists, PPAR and LXR 
activators, AMP enhancing agents and TJ component replace-
ment therapies, some of which need further clinical research to 
clarify the treatment effect on AD.
Moisturizers have a pivotal role in improving and maintaining 
the skin-barrier function and in reducing skin susceptibility to 
irritants.92 Properties of physiologic lipid-based products differ 
from nonphysiologic agents. Compared with other emollients 
that form a more superficial occlusive barrier (e.g., petrolatum), 
ceramide-dominant physiologic lipid-based products are thought 
to participate in physiologic lipid replacement therapy by per-
meating the SC, incorporating into keratinocyte synthesis, be-
coming processed in the LBs and being secreted back into the 
SC.93 The ceramide-dominant, triple-physiologic lipid barrier 
repair therapy for AD (Cer:cholesterol:free fatty acids at a 3:1:1 
molar ratio) addresses the problems of both a global reduction 
in lipids and the further decline in Cer in AD.52,94 Studies on AD 
and barrier repair treatment showed that adequate lipid re-
placement therapy reduces inflammation and restores epider-
mal barrier function comparable to that by topical fluticasone 
cream.95,96 Due to the decreased amount of ceramide in AD, the 
approach of ceramide supplementation was introduced using 
pseudoceramide, which showed a close similarity to that of SC 
intercellular lipids. The physiologic lipid vehicle mixture con-
taining pseudoceramide showed positive results in an AD 
model.97,98 Hatano et al.48 reported that steroid therapy com-
bined with PPARα ligand therapy is not only effective, but it also 
prevents the development of steroid-induced side effects, 
thereby reducing the amount of steroid required in a murine 
AD model. These studies imply that barrier repair therapy re-
duces the usage and side effects of steroid, which enhances the 
efficacy of AD treatment. These studies suggest the theoretical 
possibility that the combined treatment of calcineurin inhibi-
tors and barrier repair therapy might be a useful modality for 
Table 1. Advantages of emollient therapy
1. Emollient has a barrier corrective function
-  Normalizes the barrier (decreases cytokine cascade) and pH (decreases 
serine protease activity)
- Prevents allergen/hapten ingress
- Possesses anti-inflammatory and antimicrobial (AMP↑) properties
2. Emollient therapy could decrease the amount of steroid usage
3. Emollient therapy could decrease and/or inhibit the side effects of steroid 
therapy
4. Emollient therapy could be used as a maintenance treatment in AD
-  Might be a potentially useful treatment when combined with proac-
tive therapy such as calcineurin inhibitors and/or topical fluticasone 
propionate
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AD treatment (Table 1). Further clinical studies involving the 
combined treatment of steroid and/or other proactive thera-
pies and barrier repair therapies are needed. Urea, used in vari-
ous topical emollients, has been shown to restore barrier func-
tion (transglutaminase-1, involucrin, loricrin, FLG and epider-
mal lipid synthetic enzymes) and AMP expression (LL-37 and 
HBD2) by regulating epidermal gene expression in a murine 
AD model.99 This study suggests the potential use of urea in 
therapeutic applications for AD treatment. Histamine could ag-
gravate AD via its effects on epidermal keratinocyte differentia-
tion. In a recent study using an animal model of AD, Gschwandt-
ner et al.100 reported that histamine inhibits epidermal keratino-
cyte differentiation and skin barrier formation in organotypic 
skin models. The ability of topical histamine type 1 and 2 recep-
tor (H1/2r) antagonists to target epidermal H1/2r could translate 
into increased efficacy in the treatment of inflammatory derma-
toses, likely due to decreased inflammation and enhanced barri-
er function by stimulating the synthesis and secretion of epider-
mal lipids.91 Therefore, H1r and H2r antagonists could be used as 
a topical barrier repair therapy to treat AD.
The anti-inflammatory features of barrier repair therapy could 
be explained by several mechanisms. Normalizing the barrier 
function induces decreased cytokine cascade, prevention of al-
lergen and/or hapten ingress and increased antimicrobial de-
fense. Furthermore, certain free fatty acids have anti-inflamma-
tory properties. In addition, normalizing the pH using barrier 
repair therapy leads to downregulation of serine protease activ-
ity, which causes reduced Th2 inflammation, IL-1 activation 
and PAR2-mediated pruritus. Regarding the pathomechanisms 
described above, barrier repair therapy for AD should include a 
prolonged pH reduction in the SC (hyperacidification) and the 
application of serine protease inhibitors, topical PAR2 antago-
nists, PPAR and LXR activators, AMP-enhancing agents or re-
placement of TJ components. Further studies are needed to de-
velop novel and effective barrier repair therapies for AD on the 
basis of AD pathogenesis.
CONCLUSIONS
The epidermal permeability barrier plays a crucial role in main-
taining skin homeostasis. Perturbations in barrier function have 
significant effects on overall skin quality. The barrier anomalies 
facilitate sustained antigen ingress through the defective barri-
er, which can bring about a Th2-dominant response. It enhanc-
es the TEWL, resulting in dry skin and leading to the release of 
preformed proinflammatory cytokines and to a cascade of in-
flammatory events. These events negatively affect the epider-
mal permeability barrier function, which causes a vicious cycle 
in the skin, perhaps leading to systemic inflammation. The con-
verging pathogenic features described above provide a basis for 
the development of specific strategies to restore the barrier 
function in AD. 
The defective epidermal barrier in AD could allow the so-called 
atopic march, characterized by the epicutaneous delivery of 
antigens that induce asthma and allergic rhinitis. Although FLG 
is not expressed in either bronchial or other non-keratinizing 
mucosal epithelia, FLG deficiency is associated with mucosal 
atopy independent of AD. Based on this observation, barrier re-
pair therapy might block the development of atopic march. 
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